Anzeige
Meldung des Tages: Uran-Aktie legt nach: Vier Bohrlöcher, vier Treffer – bestätigt sich hier ein neues Uran-System?

Pfizer

Aktie
WKN:  852009 ISIN:  US7170811035 US-Symbol:  PFE Branche:  Pharmazeutika Land:  USA
25,74 $
+0,04 $
+0,16%
22,261 € 15:55:09 Uhr
Depot/Watchlist
Marktkapitalisierung *
127,66 Mrd. €
Streubesitz
30,52%
KGV
18,18
Dividende
1,53 EUR
Dividendenrendite
6,48%
Nachhaltigkeits-Score
45 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,58: UP251S
Werbung
Warnung
Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlage­strategien geeignet.

Unternehmensmeldungen

08.06.26 - Businesswire
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI ® (marstacimab-​hncq) to include the ...
06.06.26 - Businesswire
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an investigational, potential first-​in-class monthly GLP-1 receptor ...
01.06.26 - Businesswire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs ...
31.05.26 - Businesswire
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced detailed progression-​free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating ...
30.05.26 - Businesswire
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Pfizer Inc. (NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-​ribose polymerase (PARP) ...
29.05.26 - Businesswire
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-​year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a third-​generation ALK ...
27.05.26 - Businesswire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the ...
20.05.26 - Businesswire
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study ( NCT06524414 ) evaluating the safety, tolerability and immunogenicity of a four-dose series of its ...
13.05.26 - Businesswire
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI ® (marstacimab) ...
05.05.26 - Businesswire
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance (2) .
29.04.26 - Businesswire
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with ...
28.04.26 - Businesswire
Pfizer Reaches Three Settlement Agreements for VYNDAMAX
Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, ...
22.04.26 - Businesswire
Pfizer Declares Second-Quarter 2026 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-​quarter 2026 dividend on the company’s common stock, payable June 12, 2026, to ...
21.04.26 - Businesswire
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-​leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual ...
09.04.26 - Businesswire
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, ...
24.03.26 - Businesswire
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, ...
23.03.26 - Businesswire
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor ...
20.03.26 - Businesswire
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC
Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-​tender offer by Tutanota LLC (“Tutanota”) to purchase up to 1 million shares of Pfizer ...
19.03.26 - Businesswire
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-​ribose polymerase (PARP) ...
17.03.26 - Businesswire
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus ...

Newssuche

Videos

newspaper
02.06.26 -6,33%
Technical Trading: Indikator generiert Longsignal
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »